Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
74.37 EUR | -0.08% | +0.15% | +7.07% |
05-29 | UBS Adjusts DuPont de Nemours Price Target to $98 From $93, Maintains Buy Rating | MT |
05-28 | DuPont's Breakup Plan Holds Logic Amid Disadvantages, BofA Says | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- With an expected P/E ratio at 31.32 and 23.04 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The company's enterprise value to sales, at 3.24 times its current sales, is high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Sector: Diversified Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.07% | 34.35B | - | ||
-1.05% | 74.34B | B | ||
-0.76% | 46.86B | A- | ||
+9.37% | 18.1B | B | ||
+12.81% | 11.92B | A- | ||
-3.01% | 10.43B | - | ||
-20.72% | 10.33B | B | ||
-1.35% | 9.04B | A- | ||
-11.01% | 7.84B | C- | ||
-3.85% | 7.52B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- DD Stock
- 6D81 Stock
- Ratings DuPont de Nemours, Inc.